COMING 2022

THE STATE OF MEDTECH & DIGITAL HEALTH INNOVATION: A NEW DECADE

Landmark study on the impact of MedTech and Digital Health regulation and reimbursement from 2010 to 2020

Today's MedTech leaders shaping tomorrow's regulatory landscape

In 2020, executive leaders from medtech and digital health companies participated in  interviews to share their experience and recommendations for industry priorities for regulatory and reimbursement in the new decade. 
 
Conducted by a leading university, this IRB exempt study specifically interviewed founders, CEOs, and regulatory executive thought-leaders across medtech and digital health to examine trends, establish benchmarks, and inform future decision-making for regulatory and reimbursement. 

 

MedTech & Digital Innovation study featured on DeviceTalks

Kwame Ulmer, study co-lead and former FDA deputy director and branch chief, sits down with Tom Salemi at DeviceTalks to share how this study aims to bring together the innovation ecosystem to be a part of breakthrough research to inform the advancement of regulatory and reimbursement. 

DTpod21_Herrera-Ulmer_1200x627_Vs1.jpg
 

What questions are explored? 

hourglass.png

How long does it really take innovations to get to market?

Location.png

Do digital health and AI / ML have a clear path to market?

rocket.png

Is breakthrough designation breaking down regulatory barriers to access?

obstacle.png

Is reimbursement the new barrier to innovation?

earth.png

Is the U.S. the prioritized global regulatory path to 1st approval?

Looking Ahead.png

What is next on the regulatory and reimbursement horizon?

 

What information was examined?

MedTech and Digital Health companies shared insight on:

required to achieve one of the following FDA pathways for a medtech product:

510(k)

PMA

De Novo

Stock Exchange
money_edited_edited_edited.png

Cost

The Time
clock_edited_edited_edited_edited_edited

Time

Doctor Using Digital Tablet
support_edited_edited.png

Experience

On the Phone
review_edited_edited.png

Perspective

Which global regulatory markets were examined?

USmap3d.jpg

U.S. FDA

EUmap 3D.jpg

European CE Mark

Japan Icon.jpg

Japan PMDA

ChinaMap3D.gif

China NMPA

When will the study report be launched?

Industry report will be presented at leading conferences in 2022
Jennifer McCaney Photo_square.jpg

Jennifer McCaney, PhD

Co-Executive Director, UCLA Biodesign 

Assistant Professor at the UCLA Anderson School of Management and Geffen School of Medicine, former Director of Medtech Innovator. 

KWAME-8960.jpg

Kwame Ulmer, MBA

Lecturer, UCLA Anderson  

Venture Partner at Wavemaker Three-Sixty Health former medtech executive, former Deputy Director at the FDA, and founder of Medtech Color. 

Heashot CKJ White Background.png

Christian Johnson, MBA

Sr. Fellow, UCLA Biodesign

Co-Founder and Board Member of Seed Consulting Group, former strategist and marketer at Edwards Lifesciences and various startups.

Who is leading the research?

Be among the first to receive the report

Want to receive results immediately once available in 2022? Sign up to receive the study report. 

Sign Up to Receive Study Report

Thanks for submitting! You will receive a copy of the study report when it is available

 
 

Want to learn more? 

1001 Gayley Avenue, Suite 216
Los Angeles, CA 90095

About this study

This study is strictly an independent research study led by the University of California Los Angeles. The investigators have no conflicts of interest to disclose. Individual company data will not be released to any regulatory bodies or entities. Study results will be published in aggregate for the benefit of advancing innovation in medical technology and digital health. This research has been certified as exempt from IRB review per 45 CFR 46.104 category 2 (IRB#20-001604).